Skip to Content

Medite Cancer Diagnostics Inc MDIT Stock Quote

| Rating as of


Market Closed

| Currency in USD

  • Last Close < 0.01
  • Sector Healthcare
  • Industry Medical Instruments & Supplies
  • Investment Style
  • Day Range < 0.01  –  < 0.01
  • Year Range < 0.01  –  < 0.01
  • Market Cap 8,672.3700
  • Volume / Avg 217.0 /  458.9
  • Price / Sales
  • Price / Book
  • Forward Div Yield 3.23%
  • Trailing Div Yield

Morningstar‘s Stock Analysis MDIT

Currency in
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price


5-Star Price


Economic Moat


About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics MDIT

Company Profile MDIT

Business Description

Medite Cancer Diagnostics Inc is a US-based company which specializes in the marketing and selling of MEDITE core products (instruments and consumables), manufacturing, development of new solutions in histology and cytology and marketing of molecular biomarkers. The company manufactures medical devices and consumables are for detection, risk assessment and diagnosis of cancerous and precancerous conditions and related diseases. Medite operates through the single segment for cancer diagnostics instruments and consumables for histology and cytology laboratories. It offers a range of histology laboratory devices for processing tissue, from receiving the tissue in the laboratory to the final diagnosis.

4203 SouthWest 34th Street
Orlando, FL, 32811
Industry Medical Instruments & Supplies
Employees 69

Competitors & Peers MDIT

Morningstar does not cover competitors or peers for this firm.

FAQs for Medite Cancer Diagnostics Inc Stock

No. MDIT does not currently have a forward dividend yield.
Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.

Learn more about dividend yield.

MDIT’s market cap is 8,672.37.
Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares. It’s often used to measure a company’s size. In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.

Learn more about market capitalization.

MDIT’s stock style is Small Growth.
Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated.

High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends.

Learn more about style.

MDIT’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.

Compare MDIT’s historical performance against its industry peers and the overall market.